Cytokinetics (CYTK) EBT (2016 - 2024)
Historic EBT for Cytokinetics (CYTK) over the last 16 years, with Q4 2024 value amounting to -$148.0 million.
- Cytokinetics' EBT fell 995.38% to -$148.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$573.9 million, marking a year-over-year decrease of 942.55%. This contributed to the annual value of -$573.9 million for FY2024, which is 942.55% down from last year.
- Per Cytokinetics' latest filing, its EBT stood at -$148.0 million for Q4 2024, which was down 995.38% from -$149.7 million recorded in Q3 2024.
- In the past 5 years, Cytokinetics' EBT registered a high of $1.2 million during Q3 2020, and its lowest value of -$149.7 million during Q3 2024.
- In the last 5 years, Cytokinetics' EBT had a median value of -$97.9 million in 2022 and averaged -$87.7 million.
- As far as peak fluctuations go, Cytokinetics' EBT surged by 10478.0% in 2020, and later crashed by 617301.32% in 2021.
- Quarter analysis of 5 years shows Cytokinetics' EBT stood at -$40.4 million in 2020, then surged by 35.88% to -$25.9 million in 2021, then tumbled by 417.27% to -$134.1 million in 2022, then dropped by 0.37% to -$134.6 million in 2023, then dropped by 9.95% to -$148.0 million in 2024.
- Its last three reported values are -$148.0 million in Q4 2024, -$149.7 million for Q3 2024, and -$142.9 million during Q2 2024.